Clinical Trials Information
Nektar Therapeutics is focused on the clinical development of our investigational medicines to evaluate them for both safety and efficacy, especially for medical conditions where there are no effective approved medicines.
Before a new therapy can be made available to the general public, rigorous tests involving multiple studies on human volunteers are required. These studies, referred to as clinical trials, are carefully conducted and are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide. Participation in clinical trials allows patients to potentially gain access to the latest investigational treatments at little to no cost, while also playing a vital role in advancing medicine.
Nektar Therapeutics is recruiting patients in the U.S. and other countries for the following active clinical trials. Please follow the links below for more information on the enrollment criteria for each study and site location:
A phase 2 study of REZPEG (NKTR-358) (LY3471851) in adults with systemic lupus erythematosus (SLE)
More information on REZPEG (NKTR-358)
A Phase 2/3, randomized, double blind, placebo-controlled, multicenter study of NKTR-255 vs placebo following CD-19 directed CAR-T therapy in patients with relapsed/refractory large B-cell lymphoma
A phase 1/2, dose-escalation and dose-expansion study of NKTR-255 in combination with cetuximab in patients with refractory 2nd and 3rd line metastatic colorectal cancer or metastatic head and neck cancer
A Phase 1 study of NKTR-255 following CD-19/22 directed CAR-T therapy in patients with CD-19 positive B acute lymphoblastic leukemia
In April 2022, Nektar Therapeutics and Bristol Myers Squibb announced that the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. These studies and all other ongoing studies in the program will be discontinued, allowing patients and their physicians to consider standard of care treatment options for their specific conditions.
A phase 3, randomized study of bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) compared with the investigator’s choice of tyrosine kinase inhibitor therapy (either sunitinib or cabozantinib) for previously untreated advanced RCC
A phase 2, single-arm study of bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) in cisplatin-ineligible, locally advanced or metastatic urothelial cancer
A phase 1/2, open-label, multicenter study of bempegaldesleukin (BEMPEG; NKTR-214) in combination with pembrolizumab in locally advanced or metastatic solid tumors, including NSCLC
A phase 2 study of the triplet combination of bempegaldesleukin with nivolumab (NIVO) and cabozantinib (CABO) versus NIVO plus CABO for the treatment of renal cell carcinoma that is advanced or has spread
More information on Bempegaldesleukin
Further information and background on clinical trials may be found on www.clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH).